Figure 6.

AZD6738, an ATR inhibitor, in combination with belotecan demonstrates synergism in vitro primary ovarian cancer cells: (a) schematic diagram for the collection of ascitic fluid from ovarian cancer patients and the culture of primary cancer cells. (b) Representative image of H&E staining, which confirmed that the CHA-OVA-18 cells were ovarian cancer cells. (c,d) Combination of belotecan and AZD6738—in a constant combination ratio of both drugs—demonstrated synergistic cytotoxicity in both CHA-OVA-9 (platinum-sensitive) (c) and CHA-OVA-18 (platinum-resistant) primary ovarian cancer cells (d). (e) Bar graph representing the comparison of IC₅₀ among the three primary ovarian cancer cells—namely CHA-OVA-9, CHA-OVA-16, and CHA-OVA-18.